

REMARKS/ARGUMENTS

Status of the claims

Applicants have amended claims 1, 11, and 46 for the purposes of clarity in this Office Action response. Claims 54 and 55 have been canceled as being dependent on a previously canceled claim. Accordingly, claims 1-32, 37, 45-53, and 56 are pending for examination. Reconsideration is respectfully requested in light of the remarks which follow.

Advisory Action

Applicants thank the Examiner for the Advisory Action mailed August 27, 2007. In the Advisory Action, the Examiner maintained his objection to the use of the term "prevent" in the claims for alleged lack of enablement. In the interest of expediting prosecution, Applicants have amended claims 1, 11, and 46 to remove the term "prevent", thus obviating this ground for rejection. Accordingly, claims 1, 11, and 46, as amended, now recite, in part, "A is a peptide portion of about 2 to about 20 acidic amino acid residues, which when linked with portion B is effective to inhibit cellular uptake of portion B". As discussed in detail below with respect to the rejection made in the Office Action, Applicants respectfully submit that the specification provides full enablement support for the inhibition of the cellular uptake of a basic portion B by an acidic portion A in the context of the molecular structure A-X-B.

Claim rejections under 35 U.S.C. § 112, first paragraph - enablement

Claims 1-32, 37, 45-48, and 54-56 stand rejected under 35 U.S.C. § 112, first paragraph, as allegedly failing to comply with the enablement requirement. To the extent that this rejection applies to the amended claims, Applicants respectfully traverse.

In order for a claim to be enabled, the specification, when filed, must contain sufficient information regarding the subject matter of the claims as to enable one skilled in the pertinent art to make and use the claimed invention without undue experimentation. *See* MPEP 2164.01. As discussed below, the specification provides more than adequate information on how to make and use the presently claimed invention without undue experimentation.

In making this rejection, the Examiner notes that in the previous Office Action response, in response to an enablement rejection, Applicants asserted that the specification

provided ample evidence that an acidic amino acid containing portion, **A**, is able to prevent the uptake of a linked basic portion **B**, pointing to Examples 3-6 and Figures 7-11 of the specification to provide enablement support for the use of the term "prevent". *See Office Action at page 3.*

The Examiner has not accepted Applicants' previous arguments for enablement and has maintained the enablement rejection in the present Office Action, by alleging that "none of the peptides of Examples 3-6 and Figures 7-11 include SEQ ID NO: 1 as set forth in the amended claims". *See Office Action at page 3.* In reviewing the disclosures presented in Example 3, the Examiner states that "Applicants have shown that cellular uptake is prevented at very specific conditions", but that "independent claims 1, 11, and 46 are not limited to such conditions". *See Office Action at page 3.* Applicants respectfully disagree with the Examiner's characterization of what the present specification teaches and whether this is reflected in the claim language.

As mentioned above, in order to expedite prosecution, Applicants have amended claims 1, 11, and 46 to remove recitation of the term "prevents", thus obviating the grounds for rejection based on the use of this term.

Furthermore, Applicants respectfully submit that the Examiner is in error by alleging that "none of the peptides of Examples 3-6 and figures 7-11 include SEQ ID NO: 1 as set forth in the claims". *See Office Action at page 3.* The sequence of SEQ ID NO: 1 is PLGLAG. Applicants respectfully submit that SEQ ID NO: 13 in Example 3 contains SEQ ID NO: 1 (PLGLAG) as part of its sequence.

Moreover, Applicants respectfully submit that the specification provides full enablement support for amended claims 1, 11, and 46, which recite, in part, "**A** is a peptide portion of about 2 to about 20 acidic amino acid residues, which when linked with portion **B** is effective to inhibit cellular uptake of portion **B**". For example, as disclosed in the specification at page 19, paragraph [0061], the sequence PLGLAG can be used as a linker, **X**, which is cleavable by the metalloproteinase MMP-2. Example 4 and Figures 7A and 7B of the specification show that a peptide containing the sequence PLGLAG of SEQ ID NO: 1 can be

efficiently cleaved by MMP-2 protease. Example 5 and Figures 11 and 12 show that the uptake of a peptide of the structure **A-X-B** (Fl) (SEQ ID NO: 13; where Fl is a fluorescein label) into Jurkat cells is increased 10-20-fold after cleavage of the peptide at the PLGLAG linker site. Thus, Applicants respectfully submit that these results demonstrate the inhibition of cellular uptake of compounds having basic amino acids (**B**) by linkage to an acidic portion (**A**) because the uptake of a moiety containing the fluorescent label (**B** (Fl)) is increased by 10-20-fold after removal of the inhibitory portion **A** from the molecular structure **A-X-B** (Fl). As pointed out in the specification, "these results demonstrate enhanced cellular uptake of fluorescent portions of these peptides (having basic amino acids) following cleavage of the acidic portions." *See* specification at page 36, paragraph [00104].

Accordingly, Applicants respectfully disagree with the Examiner's allegation that independent claims 1, 11, and 46 do not recite the conditions described in the specification, particularly those in Examples 3-6 and their corresponding figures. Rather, as reflected in the claim language, the specification sets forth a molecule of the structure **A-X-B** (Fl), wherein **B** is a peptide portion of about 5 to about 20 basic amino acid residues (*e.g.*, *rrrrrrr* in SEQ ID NO: 13, among other examples), which is suitable for cellular uptake (*e.g.*, Example 5 and Figures 11 and 12 (7-6 peptide), among others), as claimed. Furthermore, as described in the specification and claimed, **A** is a peptide of about 2 to about 20 acidic amino acid residues (*e.g.*, *eeeeee* in SEQ ID NO: 13, among other examples), which when linked with portion **B** is effective to inhibit cellular uptake of portion **B** (*e.g.*, Example 5 and Figures 11 and 12 (7-6 peptide), among others). Finally, as described in the specification and claimed, **X** is a linker of about 2 to about 100 atoms joining **A** with **B** (*i.e.*, the sequence PLGLAG contained within SEQ ID NO: 13), which can be cleaved upon physiological conditions (*e.g.*, Example 4), wherein **X** comprises the sequence of SEQ ID NO: 1 (*i.e.*, the sequence PLGLAG contained within SEQ ID NO: 13). Claim 11 further recites **C**, which is a portion comprising a cargo moiety (*e.g.*, Fl in SEQ ID NO: 13), as described in the specification.

In addition to providing enablement for the inhibition of cellular uptake of peptides of the invention when the PLGLAG sequence (SEQ ID NO: 1) is used as a cleavable

linker as claimed, the specification and examples contained therein describe other types of cleavable linkers that may be used. The sequence PLGLAG, as well as, other linker sequences disclosed in the present specification are well characterized cleavage sites for variety of proteases (e.g., MMP-2 in the case of PLGLAG). Because these linker sequences are provided in the context of peptides, cleavage sites within the linker sequences are readily accessible to the action of their cognate proteases under physiological conditions. Thus, the skilled artisan would be able to predictably make and use the A-X-B or A-X-B-C compositions of the present invention with no more than routine experimentation.

For the foregoing reasons, Applicants respectfully submit that the inhibition of cellular uptake of the peptide compositions as claimed is amply enabled by the teachings of the specification. Accordingly, Applicants respectfully request withdrawal of this ground for rejection.

Claim rejection under obviousness-type double patenting

Claim 11 stands provisionally rejected on the grounds of nonstatutory obviousness-type double patenting as allegedly being unpatentable over claims 1, 6, and 21 of copending Application No. 11/133,804.

In the interest of expediting prosecution, Applicants respectfully request that this rejection be held in abeyance until such time as the application is otherwise deemed to be in condition for allowance. If the other application is pending upon the allowance of the present application, then this rejection should be withdrawn.

Claim rejections under 35 U.S.C. § 112, second paragraph - indefiniteness


Claims 54 and 55 stand rejected under 35 U.S.C. § 112, second paragraph, as indefinite for reciting dependence upon canceled claim 39. Applicants thank the Examiner for bringing this to the attention of Applicants. Applicants have canceled claims 54 and 55, thus obviating this ground for rejection.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance and an action to that end is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,

A handwritten signature in cursive script that reads "Gene H. Yee".

Gene H. Yee
Reg. No. 57,471

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 415-576-0300
GHY:lls
61084939 v1